{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:12:22Z","timestamp":1791663142514,"version":"4.3.4"},"reference-count":237,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["#26246"],"award-info":[{"award-number":["#26246"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["#30782"],"award-info":[{"award-number":["#30782"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["#2022AA4FTJ"],"award-info":[{"award-number":["#2022AA4FTJ"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["P2022YAKJY"],"award-info":[{"award-number":["P2022YAKJY"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-025-00644-w","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T22:51:37Z","timestamp":1749077497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms"],"prefix":"10.1007","volume":"14","author":[{"given":"Linda","family":"Manna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Antonia","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"And\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bonofiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-0607","authenticated-orcid":false,"given":"Cinzia","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3184-2724","authenticated-orcid":false,"given":"Ines","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"644_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN guidelines\u00ae insights: multiple myeloma, version 3.2022. J Natl Compr Canc Netw. 2022;20:8\u201319.","journal-title":"J Natl Compr Canc Netw"},{"key":"644_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"644_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","volume":"33","author":"K Brigle","year":"2017","unstructured":"Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33:225\u201336.","journal-title":"Semin Oncol Nurs"},{"key":"644_CR4","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos M-V. Smoldering multiple myeloma. Blood. 2015;125:3069\u201375.","journal-title":"Blood"},{"key":"644_CR5","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"644_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14712598.2023.2193289","volume":"23","author":"EA Martino","year":"2023","unstructured":"Martino EA, Bruzzese A, Iaccino E, Mendicino F, Mimmi S, Lucia E, et al. Isatuximab in multiple myeloma. Expert Opin Biol Ther. 2023;23:315\u20138.","journal-title":"Expert Opin Biol Ther"},{"key":"644_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14712598.2022.2145882","volume":"23","author":"A Bruzzese","year":"2023","unstructured":"Bruzzese A, Martino EA, Vigna E, Iaccino E, Mendicino F, Lucia E, et al. Elotuzumab in multiple myeloma. Expert Opin Biol Ther. 2023;23:7\u201310.","journal-title":"Expert Opin Biol Ther"},{"key":"644_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/14712598.2023.2218543","volume":"23","author":"EA Martino","year":"2023","unstructured":"Martino EA, Bruzzese A, Iaccino E, Labanca C, Mendicino F, Mimmi S, et al. Belantamab mafodotin in multiple myeloma. Expert Opin Biol Ther. 2023;23:1043\u20137.","journal-title":"Expert Opin Biol Ther"},{"key":"644_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.hoc.2023.12.002","volume":"38","author":"NWCJ van de Donk","year":"2024","unstructured":"van de Donk NWCJ, Zweegman S. Monoclonal antibodies in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 2024;38:337\u201360.","journal-title":"Hematol Oncol Clin North Am"},{"key":"644_CR10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ejh.14121","volume":"112","author":"EA Martino","year":"2024","unstructured":"Martino EA, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, et al. Teclistamab-cqyv in multiple myeloma. Eur J Haematol. 2024;112:320\u20137.","journal-title":"Eur J Haematol"},{"key":"644_CR11","doi-asserted-by":"publisher","first-page":"101251","DOI":"10.1016\/j.blre.2024.101251","volume":"69","author":"G Shouse","year":"2025","unstructured":"Shouse G. Bispecific antibodies for the treatment of hematologic malignancies: the magic is T-cell redirection. Blood Rev. 2025;69:101251.","journal-title":"Blood Rev"},{"key":"644_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ejh.14353","volume":"114","author":"C Labanca","year":"2025","unstructured":"Labanca C, Martino EA, Vigna E, Bruzzese A, Mendicino F, Lucia E, et al. Talquetamab in multiple myeloma: efficacy, safety, and future directions. Eur J Haematol. 2025;114:386\u201399.","journal-title":"Eur J Haematol"},{"key":"644_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan D, Madduri D, Hocking J. CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J. 2024;14:206.","journal-title":"Blood Cancer J"},{"key":"644_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Medical Sciences. 2021;9:3.","journal-title":"Medical Sciences"},{"key":"644_CR15","doi-asserted-by":"crossref","unstructured":"Jurczyszyn A, Suska A. Multiple myeloma. Encyclopedia of biomedical gerontology, academic press. 2019;461\u201378.","DOI":"10.1016\/B978-0-12-801238-3.11412-6"},{"key":"644_CR16","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","volume":"116","author":"AJ Waxman","year":"2010","unstructured":"Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116:5501\u20136.","journal-title":"Blood"},{"key":"644_CR17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma. JAMA Oncol. 2018;4:1221.","journal-title":"JAMA Oncol"},{"key":"644_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.14199","volume":"175","author":"LH Schinasi","year":"2016","unstructured":"Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, et al. Multiple myeloma and family history of lymphohaematopoietic cancers: results from the International Multiple Myeloma Consortium. Br J Haematol. 2016;175:87\u2013101.","journal-title":"Br J Haematol"},{"key":"644_CR19","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.clml.2023.02.004","volume":"23","author":"J Kaur","year":"2023","unstructured":"Kaur J, Valisekka SS, Hameed M, Bandi PS, Varma S, Onwughalu CJ, et al. Monoclonal gammopathy of undetermined significance: a comprehensive review. Clin Lymphoma Myeloma Leuk. 2023;23:e195-212.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"644_CR20","doi-asserted-by":"publisher","first-page":"000","DOI":"10.14218\/JERP.2022.00059","volume":"000","author":"OC Nwabuko","year":"2023","unstructured":"Nwabuko OC. Multiple myeloma: risk factors, pathogenesis and relationship with anti-myeloma therapies. J Explor Res Pharmacol. 2023;000:000\u2013000.","journal-title":"J Explor Res Pharmacol"},{"key":"644_CR21","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4103\/0377-4929.91504","volume":"54","author":"M Sadeghian","year":"2011","unstructured":"Sadeghian M, Ayatollahi H, Keramati M, Memar B, Jamedar S, Avval M, et al. The association of Epstein-Barr Virus infection with multiple myeloma. Indian J Pathol Microbiol. 2011;54:720.","journal-title":"Indian J Pathol Microbiol"},{"issue":"276","key":"644_CR22","first-page":"1851","volume":"1997","author":"MB Rettig","year":"1979","unstructured":"Rettig MB, Ma HJ, Vescio RA, P\u00f5ld M, Schiller G, Belson D, et al. Kaposi\u2019s sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science. 1979;1997(276):1851\u20134.","journal-title":"Science"},{"key":"644_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2023.04.003","volume":"92","author":"A Tentolouris","year":"2023","unstructured":"Tentolouris A, Ntanasis-Stathopoulos I, Terpos E. Obesity and multiple myeloma: emerging mechanisms and perspectives. Semin Cancer Biol. 2023;92:45\u201360.","journal-title":"Semin Cancer Biol"},{"key":"644_CR24","unstructured":"Weir CB, Jan A. BMI classification percentile and cut off points. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025."},{"key":"644_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/2008-7802.183654","volume":"7","author":"N Ahmad","year":"2016","unstructured":"Ahmad N, Adam SM, Nawi A, Hassan M, Ghazi H. Abdominal obesity indicators: waist circumference or waist-to-hip ratio in Malaysian adults population. Int J Prev Med. 2016;7:82.","journal-title":"Int J Prev Med"},{"key":"644_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1152\/physrev.00033.2011","volume":"93","author":"A Tchernof","year":"2013","unstructured":"Tchernof A, Despr\u00e9s J-P. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359\u2013404.","journal-title":"Physiol Rev"},{"key":"644_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-med-051613-012328","volume":"66","author":"PJ Goodwin","year":"2015","unstructured":"Goodwin PJ, Stambolic V. Impact of the obesity epidemic on cancer. Annu Rev Med. 2015;66:281\u201396.","journal-title":"Annu Rev Med"},{"key":"644_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/BF01694762","volume":"5","author":"GD Friedman","year":"1994","unstructured":"Friedman GD, Herrinton LJ. Obesity and multiple myeloma. Cancer Causes Control. 1994;5:479\u201383.","journal-title":"Cancer Causes Control"},{"key":"644_CR29","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/1055-9965.EPI-16-0762-T","volume":"26","author":"BM Birmann","year":"2017","unstructured":"Birmann BM, Andreotti G, De Roos AJ, Camp NJ, Chiu BCH, Spinelli JJ, et al. Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the International Multiple Myeloma Consortium (IMMC). Cancer Epidemiol Biomarkers Prev. 2017;26:876\u201385.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"644_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/bjh.12935","volume":"166","author":"LR Teras","year":"2014","unstructured":"Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, Robien K, et al. Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol. 2014;166:667\u201376.","journal-title":"Br J Haematol"},{"key":"644_CR31","doi-asserted-by":"publisher","first-page":"1611338","DOI":"10.3389\/pore.2023.1611338","volume":"29","author":"W Tie","year":"2023","unstructured":"Tie W, Ma T, Yi Z, Liu J, Li Y, Bai J, et al. Obesity as a risk factor for multiple myeloma: insight on the role of adipokines. Pathol Oncol Res. 2023;29:1611338.","journal-title":"Pathol Oncol Res"},{"key":"644_CR32","doi-asserted-by":"publisher","first-page":"9159","DOI":"10.1002\/jcp.26884","volume":"233","author":"EV Morris","year":"2018","unstructured":"Morris EV, Edwards CM. Adipokines, adiposity, and bone marrow adipocytes: dangerous accomplices in multiple myeloma. J Cell Physiol. 2018;233:9159\u201366.","journal-title":"J Cell Physiol"},{"key":"644_CR33","doi-asserted-by":"publisher","first-page":"djw264","DOI":"10.1093\/jnci\/djw264","volume":"109","author":"S-H Chang","year":"2017","unstructured":"Chang S-H, Luo S, Thomas TS, O\u2019Brian KK, Colditz GA, Carlsson NP, et al. Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study. J Natl Cancer Inst. 2017;109:djw264.","journal-title":"J Natl Cancer Inst"},{"key":"644_CR34","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/bloodadvances.2017007609","volume":"1","author":"M Thordardottir","year":"2017","unstructured":"Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, et al. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Adv. 2017;1:2186\u201392.","journal-title":"Blood Adv"},{"key":"644_CR35","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00256-016-2425-4","volume":"45","author":"J Veld","year":"2016","unstructured":"Veld J, O\u2019Donnell EK, Reagan MR, Yee AJ, Torriani M, Rosen CJ, et al. Abdominal adipose tissue in MGUS and multiple myeloma. Skeletal Radiol. 2016;45:1277\u201383.","journal-title":"Skeletal Radiol"},{"key":"644_CR36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.clml.2021.01.008","volume":"21","author":"R Georgakopoulou","year":"2021","unstructured":"Georgakopoulou R, Andrikopoulou A, Sergentanis TN, Fiste O, Zagouri F, Gavriatopoulou M, et al. Overweight\/obesity and monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma Leuk. 2021;21:361\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"644_CR37","doi-asserted-by":"publisher","first-page":"6615684","DOI":"10.1155\/2021\/6615684","volume":"2021","author":"AD da Cunha J\u00fanior","year":"2021","unstructured":"da Cunha J\u00fanior AD, Zanette DL, Pericole FV, Olalla Saad ST, Barreto Campello Carvalheira J. Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment? Adv Hematol. 2021;2021:6615684.","journal-title":"Adv Hematol."},{"key":"644_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41408-022-00659-9","volume":"12","author":"G Kleinstern","year":"2022","unstructured":"Kleinstern G, Larson DR, Allmer C, Norman AD, Muntifering G, Sinnwell J, et al. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County. Minnesota Blood Cancer J. 2022;12:67.","journal-title":"Minnesota Blood Cancer J"},{"key":"644_CR39","first-page":"626","volume":"89","author":"MA Thompson","year":"2004","unstructured":"Thompson MA, Kyle RA, Melton LJ, Plevak MF, Rajkumar SV. Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study. Haematologica. 2004;89:626\u20138.","journal-title":"Haematologica"},{"key":"644_CR40","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","volume":"116","author":"O Landgren","year":"2010","unstructured":"Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 2010;116:1056\u20139.","journal-title":"Blood"},{"key":"644_CR41","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/leu.2014.34","volume":"28","author":"O Landgren","year":"2014","unstructured":"Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28:1537\u201342.","journal-title":"Leukemia"},{"key":"644_CR42","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S2352-3026(14)00037-4","volume":"2","author":"S-H Chang","year":"2015","unstructured":"Chang S-H, Luo S, O\u2019Brian KK, Thomas TS, Colditz GA, Carlsson NP, et al. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. Lancet Haematol. 2015;2:e30\u20136.","journal-title":"Lancet Haematol"},{"key":"644_CR43","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/10428194.2016.1236375","volume":"58","author":"B Boursi","year":"2017","unstructured":"Boursi B, Mamtani R, Yang Y-X, Weiss BM. Impact of metformin on the progression of MGUS to multiple myeloma. Leuk Lymphoma. 2017;58:1265\u20137.","journal-title":"Leuk Lymphoma"},{"key":"644_CR44","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00277-019-03825-5","volume":"98","author":"B Schmidt","year":"2019","unstructured":"Schmidt B, Debold E, Frank M, Arendt M, Dragano N, D\u00fcrig J, et al. Socioeconomic position is positively associated with monoclonal gammopathy of undetermined significance in a population-based cohort study. Ann Hematol. 2019;98:2761\u20137.","journal-title":"Ann Hematol"},{"key":"644_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1023\/B:CACO.0000016573.79453.ba","volume":"15","author":"C Samanic","year":"2004","unstructured":"Samanic C, Gridley G, Chow W-H, Lubin J, Hoover RN, Fraumeni JF Jr. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control. 2004;15:35\u201344.","journal-title":"Cancer Causes Control"},{"key":"644_CR46","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/bmj.39367.495995.AE","volume":"335","author":"GK Reeves","year":"2007","unstructured":"Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134.","journal-title":"BMJ"},{"key":"644_CR47","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.ejca.2008.11.004","volume":"45","author":"KC S\u00f6derberg","year":"2009","unstructured":"S\u00f6derberg KC, Kaprio J, Verkasalo PK, Pukkala E, Koskenvuo M, Lundqvist E, et al. Overweight, obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins. Eur J Cancer. 2009;45:1232\u20138.","journal-title":"Eur J Cancer"},{"key":"644_CR48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.24803","volume":"126","author":"AG Renehan","year":"2010","unstructured":"Renehan AG, Soerjomataram I, Tyson M, Egger M, Zwahlen M, Coebergh JW, et al. Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer. 2010;126:692\u2013702.","journal-title":"Int J Cancer"},{"key":"644_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/aje\/kwj353","volume":"165","author":"A Engeland","year":"2006","unstructured":"Engeland A, Tretli S, Hansen S, Bjorge T. Height and body mass index and risk of lymphohematopoietic malignancies in two million norwegian men and women. Am J Epidemiol. 2006;165:44\u201352.","journal-title":"Am J Epidemiol"},{"key":"644_CR50","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.3390\/ijms24076192","volume":"24","author":"RB Wilson","year":"2023","unstructured":"Wilson RB, Lathigara D, Kaushal D. Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk. Int J Mol Sci. 2023;24:6192.","journal-title":"Int J Mol Sci"},{"key":"644_CR51","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ejca.2011.01.020","volume":"47","author":"A Wallin","year":"2011","unstructured":"Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer. 2011;47:1606\u201315.","journal-title":"Eur J Cancer"},{"key":"644_CR52","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/ijc.22968","volume":"121","author":"SC Larsson","year":"2007","unstructured":"Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer. 2007;121:2512\u20136.","journal-title":"Int J Cancer"},{"key":"644_CR53","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/aje\/kws295","volume":"177","author":"JN Hofmann","year":"2013","unstructured":"Hofmann JN, Moore SC, Lim U, Park Y, Baris D, Hollenbeck AR, et al. Body mass index and physical activity at different ages and risk of multiple myeloma in the NIH-AARP diet and health study. Am J Epidemiol. 2013;177:776\u201386.","journal-title":"Am J Epidemiol"},{"key":"644_CR54","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41416-018-0010-4","volume":"118","author":"CR Marinac","year":"2018","unstructured":"Marinac CR, Birmann BM, Lee I-M, Rosner BA, Townsend MK, Giovannucci E, et al. Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. Br J Cancer. 2018;118:1013\u20139.","journal-title":"Br J Cancer"},{"key":"644_CR55","doi-asserted-by":"publisher","first-page":"pkz044","DOI":"10.1093\/jncics\/pkz044","volume":"3","author":"CR Marinac","year":"2019","unstructured":"Marinac CR, Suppan CA, Giovannucci E, Song M, Kv\u00e6rner AS, Townsend MK, et al. Elucidating under-studied aspects of the link between obesity and multiple myeloma: weight pattern, body shape trajectory, and body fat distribution. JNCI Cancer Spectr. 2019;3:pkz044.","journal-title":"JNCI Cancer Spectr"},{"key":"644_CR56","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/01.ede.0000172135.61188.2d","volume":"16","author":"CK Blair","year":"2005","unstructured":"Blair CK, Cerhan JR, Folsom AR, Ross JA. Anthropometric characteristics and risk of multiple myeloma. Epidemiology. 2005;16:691\u20134.","journal-title":"Epidemiology"},{"key":"644_CR57","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3324\/haematol.13078","volume":"93","author":"JA Britton","year":"2008","unstructured":"Britton JA, Khan AE, Rohrmann S, Becker N, Linseisen J, Nieters A, et al. Anthropometric characteristics and non-Hodgkin\u2019s lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica. 2008;93:1666\u201377.","journal-title":"Haematologica"},{"key":"644_CR58","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41416-022-01907-2","volume":"127","author":"KA Bertrand","year":"2022","unstructured":"Bertrand KA, Teras LR, Deubler EL, Chao CR, Rosner BA, Wang K, et al. Anthropometric traits and risk of multiple myeloma: a pooled prospective analysis. Br J Cancer. 2022;127:1296\u2013303.","journal-title":"Br J Cancer"},{"key":"644_CR59","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625\u201338.","journal-title":"N Engl J Med"},{"key":"644_CR60","doi-asserted-by":"publisher","first-page":"djw120","DOI":"10.1093\/jnci\/djw120","volume":"108","author":"JS Sonderman","year":"2016","unstructured":"Sonderman JS, Bethea TN, Kitahara CM, Patel AV, Harvey C, Knutsen SF, et al. Multiple myeloma mortality in relation to obesity among African Americans. J Natl Cancer Inst. 2016;108:djw120.","journal-title":"J Natl Cancer Inst"},{"key":"644_CR61","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/annonc\/mdz045","volume":"30","author":"L Abar","year":"2019","unstructured":"Abar L, Sobiecki JG, Cariolou M, Nanu N, Vieira AR, Stevens C, et al. Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies. Ann Oncol. 2019;30:528\u201341.","journal-title":"Ann Oncol"},{"key":"644_CR62","doi-asserted-by":"publisher","first-page":"e0308463","DOI":"10.1371\/journal.pone.0308463","volume":"19","author":"S Mahmud","year":"2024","unstructured":"Mahmud S, Hossain MdF, Muyeed A, Nazneen S, Haque MdA, Mazumder H, et al. Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: a systematic review and meta-analysis. PLoS One. 2024;19:e0308463.","journal-title":"PLoS One"},{"key":"644_CR63","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1200\/JCO.2020.38.15_suppl.8543","volume":"38","author":"R Ershler","year":"2020","unstructured":"Ershler R, Fernandes LL, Kanapuru B, Gwise T, Kluetz PG, Theoret MR, et al. FDA analysis: impact of BMI on efficacy outcomes in multiple myeloma trials. J Clin Oncol. 2020;38:8543\u20138543.","journal-title":"J Clin Oncol"},{"key":"644_CR64","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.clml.2017.03.252","volume":"17","author":"V Roy","year":"2017","unstructured":"Roy V, Swaika A, Kumar S, Mikhael J, Chanan-Khan A, Lacy M, et al. Influence of obesity on outcomes of patients with relapsed refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17:e139\u201340.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"644_CR65","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jcyt.2024.03.481","volume":"26","author":"H Cheng","year":"2024","unstructured":"Cheng H, Sun Y, Zhang X, Chen Z, Shao L, Liu J, et al. Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy. Cytotherapy. 2024;26:832\u201341.","journal-title":"Cytotherapy"},{"key":"644_CR66","doi-asserted-by":"publisher","first-page":"S411","DOI":"10.1016\/j.jtct.2025.01.631","volume":"31","author":"S Dong","year":"2025","unstructured":"Dong S, Waqar SH Bin, Dima D, Khouri J, Ravi G, Patel KK, et al. Effect of obesity on efficacy and safety outcomes of Chimeric Antigen Receptor-T (CAR-T) therapy in Relapsed Refractory Multiple Myeloma (RRMM). Transplant Cell Ther. 2025;31:S411-2.","journal-title":"Transplant Cell Ther"},{"key":"644_CR67","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41409-020-01008-9","volume":"56","author":"A Williams","year":"2021","unstructured":"Williams A, Baruah D, Patel J, Szabo A, Chhabra S, Dhakal B, et al. Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56:225\u201331.","journal-title":"Bone Marrow Transplant"},{"key":"644_CR68","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1182\/blood-2019-125808","volume":"134","author":"MV Firsova","year":"2019","unstructured":"Firsova MV, Mendeleeva LP, Solovev MV, Savchenko VG. Outcomes of autologous hematopoietic stem cell transplantation depending on body-mass index in patients with multiple myeloma. Blood. 2019;134:5710\u20135710.","journal-title":"Blood"},{"key":"644_CR69","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.bbmt.2011.05.005","volume":"17","author":"DT Vogl","year":"2011","unstructured":"Vogl DT, Wang T, P\u00e9rez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, et al. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2011;17:1765\u201374.","journal-title":"Biol Blood Marrow Transplant"},{"key":"644_CR70","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bjh.19937","volume":"206","author":"C Marcoux","year":"2025","unstructured":"Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, et al. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. Br J Haematol. 2025;206:763\u20135.","journal-title":"Br J Haematol"},{"key":"644_CR71","doi-asserted-by":"publisher","first-page":"698.e1","DOI":"10.1016\/j.jtct.2024.01.053","volume":"30","author":"E Malek","year":"2024","unstructured":"Malek E, Kort J, Metheny L, Fu P, Li G, Hari P, et al. Impact of visceral obesity on clinical outcome and quality of life for patients with multiple myeloma: a secondary data analysis of STaMINA (BMT CTN 0702) trial. Transplant Cell Ther. 2024;30:698.e1-698.e10.","journal-title":"Transplant Cell Ther"},{"key":"644_CR72","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1182\/bloodadvances.2023010822","volume":"7","author":"R Choa","year":"2023","unstructured":"Choa R, Panaroni C, Bhatia R, Raje N. It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma. Blood Adv. 2023;7:5510\u201323.","journal-title":"Blood Adv"},{"key":"644_CR73","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cmet.2017.12.002","volume":"27","author":"RK Zwick","year":"2018","unstructured":"Zwick RK, Guerrero-Juarez CF, Horsley V, Plikus MV. Anatomical, physiological, and functional diversity of adipose tissue. Cell Metab. 2018;27:68\u201383.","journal-title":"Cell Metab"},{"key":"644_CR74","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","volume":"30","author":"F Colotta","year":"2009","unstructured":"Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073\u201381.","journal-title":"Carcinogenesis"},{"key":"644_CR75","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/10409238.2013.875514","volume":"49","author":"D Kidane","year":"2014","unstructured":"Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell ALM, et al. Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol. 2014;49:116\u201339.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"644_CR76","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2016.06.010","volume":"380","author":"EM Bullwinkle","year":"2016","unstructured":"Bullwinkle EM, Parker MD, Bonan NF, Falkenberg LG, Davison SP, DeCicco-Skinner KL. Adipocytes contribute to the growth and progression of multiple myeloma: unraveling obesity related differences in adipocyte signaling. Cancer Lett. 2016;380:114\u201321.","journal-title":"Cancer Lett"},{"key":"644_CR77","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1210\/en.2015-1477","volume":"157","author":"WP Cawthorn","year":"2016","unstructured":"Cawthorn WP, Scheller EL, Parlee SD, Pham HA, Learman BS, Redshaw CMH, et al. Expansion of bone marrow adipose tissue during caloric restriction is associated with increased circulating glucocorticoids and not with hypoleptinemia. Endocrinology. 2016;157:508\u201321.","journal-title":"Endocrinology"},{"key":"644_CR78","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11914-017-0360-5","volume":"15","author":"L Soley","year":"2017","unstructured":"Soley L, Falank C, Reagan MR. MicroRNA transfer between bone marrow adipose and multiple myeloma cells. Curr Osteoporos Rep. 2017;15:162\u201370.","journal-title":"Curr Osteoporos Rep"},{"key":"644_CR79","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fendo.2016.00067","volume":"7","author":"C Falank","year":"2016","unstructured":"Falank C, Fairfield H, Reagan MR. Signaling interplay between bone marrow adipose tissue and multiple myeloma cells. Front Endocrinol (Lausanne). 2016;7:67.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"644_CR80","doi-asserted-by":"publisher","first-page":"101856","DOI":"10.1016\/j.tranon.2023.101856","volume":"40","author":"X Wei","year":"2024","unstructured":"Wei X, Zhang Y, Wang Z, He Y, Ju S, Fu J. Bone marrow adipocytes is a new player in supporting myeloma cells proliferation and survival in myeloma microenvironment. Transl Oncol. 2024;40:101856.","journal-title":"Transl Oncol"},{"key":"644_CR81","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1182\/blood.2021013832","volume":"139","author":"C Panaroni","year":"2022","unstructured":"Panaroni C, Fulzele K, Mori T, Siu KT, Onyewadume C, Maebius A, et al. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. Blood. 2022;139:876\u201388.","journal-title":"Blood"},{"key":"644_CR82","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/jbmr.3951","volume":"35","author":"EV Morris","year":"2020","unstructured":"Morris EV, Suchacki KJ, Hocking J, Cartwright R, Sowman A, Gamez B, et al. Myeloma cells down-regulate adiponectin in bone marrow adipocytes via TNF-Alpha. J Bone Miner Res. 2020;35:942\u201355.","journal-title":"J Bone Miner Res"},{"key":"644_CR83","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1158\/0008-5472.CAN-20-1088","volume":"81","author":"H Fairfield","year":"2021","unstructured":"Fairfield H, Dudakovic A, Khatib CM, Farrell M, Costa S, Falank C, et al. Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype. Cancer Res. 2021;81:634\u201347.","journal-title":"Cancer Res"},{"key":"644_CR84","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.leu.2404658","volume":"21","author":"J Caers","year":"2007","unstructured":"Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia. 2007;21:1580\u20134.","journal-title":"Leukemia"},{"key":"644_CR85","doi-asserted-by":"publisher","first-page":"34329","DOI":"10.18632\/oncotarget.6020","volume":"6","author":"Z Liu","year":"2015","unstructured":"Liu Z, Xu J, He J, Liu H, Lin P, Wan X, et al. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 2015;6:34329\u201341.","journal-title":"Oncotarget"},{"key":"644_CR86","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049\u201358.","journal-title":"Blood"},{"issue":"14","key":"644_CR87","doi-asserted-by":"publisher","first-page":"7627","DOI":"10.3390\/ijms23147627","volume":"23","author":"P Neumeister","year":"2022","unstructured":"Neumeister P, Schulz E, Pansy K, Szmyra M, Deutsch AJ. Targeting the microenvironment for treating multiple myeloma. Int J Mol Sci. 2022;23(14):7627.","journal-title":"Int J Mol Sci"},{"key":"644_CR88","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"T Hideshima","year":"2007","unstructured":"Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585\u201398.","journal-title":"Nat Rev Cancer"},{"key":"644_CR89","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1038\/s41598-024-54193-8","volume":"14","author":"TMV Nedal","year":"2024","unstructured":"Nedal TMV, Moen SH, Roseth IA, Tryggestad SS, Aass KR, Hov GG, et al. Diet-induced obesity reduces bone marrow T and B cells and promotes tumor progression in a transplantable Vk*MYC model of multiple myeloma. Sci Rep. 2024;14:3643.","journal-title":"Sci Rep"},{"key":"644_CR90","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fimmu.2020.00245","volume":"11","author":"I B\u00e4hr","year":"2020","unstructured":"B\u00e4hr I, Spielmann J, Quandt D, Kielstein H. Obesity-associated alterations of natural killer cells and immunosurveillance of cancer. Front Immunol. 2020;11:245.","journal-title":"Front Immunol"},{"key":"644_CR91","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/blood-2012-06-438606","volume":"120","author":"JN Hofmann","year":"2012","unstructured":"Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D, et al. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood. 2012;120:4418\u201320.","journal-title":"Blood"},{"key":"644_CR92","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12902-022-00939-2","volume":"22","author":"R Liu","year":"2022","unstructured":"Liu R, Gao D, Lv Y, Zhai M, He A. Importance of circulating adipocytokines in multiple myeloma: a systematic review and meta-analysis based on case-control studies. BMC Endocr Disord. 2022;22:29.","journal-title":"BMC Endocr Disord"},{"key":"644_CR93","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1158\/0008-5472.CAN-15-2406","volume":"76","author":"JN Hofmann","year":"2016","unstructured":"Hofmann JN, Birmann BM, Teras LR, Pfeiffer RM, Wang Y, Albanes D, et al. Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals. Cancer Res. 2016;76:1935\u201341.","journal-title":"Cancer Res"},{"key":"644_CR94","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/oby.21894","volume":"25","author":"JN Hofmann","year":"2017","unstructured":"Hofmann JN, Mailankody S, Korde N, Wang Y, Tageja N, Costello R, et al. Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease. Obesity. 2017;25:1317\u201320.","journal-title":"Obesity"},{"key":"644_CR95","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10552-008-9233-7","volume":"20","author":"M Dalamaga","year":"2009","unstructured":"Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case\u2013control study. Cancer Causes Control. 2009;20:193\u20139.","journal-title":"Cancer Causes Control"},{"key":"644_CR96","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1600-0609.2009.01311.x","volume":"83","author":"JE Reseland","year":"2009","unstructured":"Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U, et al. Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol. 2009;83:460\u201370.","journal-title":"Eur J Haematol"},{"key":"644_CR97","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bjc.2017.282","volume":"117","author":"L Santo","year":"2017","unstructured":"Santo L, Teras LR, Giles GG, Weinstein SJ, Albanes D, Wang Y, et al. Circulating resistin levels and risk of multiple myeloma in three prospective cohorts. Br J Cancer. 2017;117:1241\u20135.","journal-title":"Br J Cancer"},{"key":"644_CR98","first-page":"241","volume":"28","author":"GE Pamuk","year":"2006","unstructured":"Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol. 2006;28:241\u20134.","journal-title":"Exp Oncol"},{"key":"644_CR99","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/172460080401900107","volume":"19","author":"MG Alexandrakis","year":"2004","unstructured":"Alexandrakis MG, Passam FH, Sfiridaki A, Pappa CA, Moschandrea JA, Kandidaki E, et al. Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers. 2004;19:52\u20137.","journal-title":"Int J Biol Markers"},{"key":"644_CR100","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2796.2004.01426.x","volume":"257","author":"T Me","year":"2005","unstructured":"Me T, Pe S. Adiponectin \u2013 journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167\u201375.","journal-title":"J Intern Med"},{"key":"644_CR101","doi-asserted-by":"publisher","first-page":"10697","DOI":"10.1074\/jbc.271.18.10697","volume":"271","author":"E Hu","year":"1996","unstructured":"Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271:10697\u2013703.","journal-title":"J Biol Chem"},{"key":"644_CR102","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1210\/jcem.86.5.7463","volume":"86","author":"C Weyer","year":"2001","unstructured":"Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"644_CR103","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2337\/diabetes.52.7.1779","volume":"52","author":"PA Kern","year":"2003","unstructured":"Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue. Diabetes. 2003;52:1779\u201385.","journal-title":"Diabetes"},{"key":"644_CR104","doi-asserted-by":"publisher","first-page":"461S","DOI":"10.1093\/ajcn\/83.2.461S","volume":"83","author":"AS Greenberg","year":"2006","unstructured":"Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006;83:461S-465S.","journal-title":"Am J Clin Nutr"},{"key":"644_CR105","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1038\/leu.2014.112","volume":"28","author":"EA Medina","year":"2014","unstructured":"Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GVN, Oyajobi BO. PKA\/AMPK signaling in relation to adiponectin\u2019s antiproliferative effect on multiple myeloma cells. Leukemia. 2014;28:2080\u20139.","journal-title":"Leukemia"},{"key":"644_CR106","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nature14301","volume":"520","author":"H Tanabe","year":"2015","unstructured":"Tanabe H, Fujii Y, Okada-Iwabu M, Iwabu M, Nakamura Y, Hosaka T, et al. Crystal structures of the human adiponectin receptors. Nature. 2015;520:312\u20136.","journal-title":"Nature"},{"key":"644_CR107","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1182\/blood-2011-01-330407","volume":"118","author":"JA Fowler","year":"2011","unstructured":"Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR, et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood. 2011;118:5872\u201382.","journal-title":"Blood"},{"key":"644_CR108","doi-asserted-by":"publisher","first-page":"R1220","DOI":"10.1152\/ajpregu.00397.2004","volume":"288","author":"KM Ajuwon","year":"2005","unstructured":"Ajuwon KM, Spurlock ME. Adiponectin inhibits LPS-induced NF-\u03baB activation and IL-6 production and increases PPAR\u03b32 expression in adipocytes. Am J Physiol-Regul Integr Comp Physiol. 2005;288:R1220\u20135.","journal-title":"Am J Physiol-Regul Integr Comp Physiol"},{"key":"644_CR109","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1194\/jlr.M800046-JLR200","volume":"49","author":"SJ Peterson","year":"2008","unstructured":"Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, et al. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res. 2008;49:1658\u201369.","journal-title":"J Lipid Res"},{"key":"644_CR110","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35053000","volume":"409","author":"CM Steppan","year":"2001","unstructured":"Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307\u201312.","journal-title":"Nature"},{"key":"644_CR111","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0006-291X(02)02841-3","volume":"300","author":"L Patel","year":"2003","unstructured":"Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR\u03b3 activators. Biochem Biophys Res Commun. 2003;300:472\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"644_CR112","doi-asserted-by":"publisher","first-page":"12522","DOI":"10.1038\/s41598-018-30978-6","volume":"8","author":"L Qiu","year":"2018","unstructured":"Qiu L, Zhang G-F, Yu L, Wang H-Y, Jia X-J, Wang T-J. Novel oncogenic and chemoresistance-inducing functions of resistin in ovarian cancer cells require miRNAs-mediated induction of epithelial-to-mesenchymal transition. Sci Rep. 2018;8:12522.","journal-title":"Sci Rep"},{"key":"644_CR113","doi-asserted-by":"publisher","first-page":"18923","DOI":"10.1038\/srep18923","volume":"6","author":"JO Lee","year":"2016","unstructured":"Lee JO, Kim N, Lee HJ, Lee YW, Kim SJ, Park SH, et al. Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Sci Rep. 2016;6:18923.","journal-title":"Sci Rep"},{"key":"644_CR114","doi-asserted-by":"publisher","first-page":"9751","DOI":"10.3390\/ijms14059751","volume":"14","author":"L Pang","year":"2013","unstructured":"Pang L, Zhang Y, Yu Y, Zhang S. Resistin promotes the expression of vascular endothelial growth factor in ovary carcinoma cells. Int J Mol Sci. 2013;14:9751\u201366.","journal-title":"Int J Mol Sci"},{"key":"644_CR115","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1530\/REP-15-0255","volume":"150","author":"A Rak","year":"2015","unstructured":"Rak A, Drwal E, Wr\u00f3bel A, Gregoraszczuk E\u0141. Resistin is a survival factor for porcine ovarian follicular cells. Reproduction. 2015;150:343\u201355.","journal-title":"Reproduction"},{"key":"644_CR116","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cardiores.2006.01.015","volume":"70","author":"H Mu","year":"2006","unstructured":"Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res. 2006;70:146\u201357.","journal-title":"Cardiovasc Res"},{"key":"644_CR117","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1055\/s-0030-1263111","volume":"119","author":"M Owecki","year":"2010","unstructured":"Owecki M, Miczke A, Nikisch E, Pupek-Musialik D, Sowi\u0144ski J. Serum resistin concentrations are higher in human obesity but independent from insulin resistance. Exp Clin Endocrinol Diabetes. 2010;119:117\u201321.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"644_CR118","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3324\/haematol.2016.154062","volume":"102","author":"J Pang","year":"2017","unstructured":"Pang J, Shi Q, Liu Z, He J, Liu H, Lin P, et al. Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression. Haematologica. 2017;102:1273\u201380.","journal-title":"Haematologica"},{"issue":"12","key":"644_CR119","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.3390\/biom11121836","volume":"11","author":"I Barone","year":"2021","unstructured":"Barone I, Giordano C. Leptin and beyond: actors in cancer. Biomolecules. 2021;11(12):1836.","journal-title":"Biomolecules."},{"key":"644_CR120","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1189\/jlb.68.4.437","volume":"68","author":"G Fantuzzi","year":"2000","unstructured":"Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68:437\u201346.","journal-title":"J Leukoc Biol"},{"key":"644_CR121","doi-asserted-by":"publisher","first-page":"86075","DOI":"10.18632\/oncotarget.13342","volume":"7","author":"W Yu","year":"2016","unstructured":"Yu W, Cao D-D, Li Q, Mei H, Hu Y, Guo T. Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy. Oncotarget. 2016;7:86075\u201386.","journal-title":"Oncotarget"},{"key":"644_CR122","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/cei.12196","volume":"175","author":"AC Chan","year":"2013","unstructured":"Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM, et al. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol. 2013;175:49\u201358.","journal-title":"Clin Exp Immunol"},{"key":"644_CR123","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clim.2010.12.010","volume":"140","author":"MV Dhodapkar","year":"2011","unstructured":"Dhodapkar MV, Richter J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol. 2011;140:160\u20136.","journal-title":"Clin Immunol"},{"key":"644_CR124","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1038\/leu.2017.146","volume":"31","author":"M Favreau","year":"2017","unstructured":"Favreau M, Menu E, Gaublomme D, Vanderkerken K, Faict S, Maes K, et al. Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma. Leukemia. 2017;31:2678\u201385.","journal-title":"Leukemia"},{"key":"644_CR125","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/biomedicines11020644","volume":"11","author":"F Deepika","year":"2023","unstructured":"Deepika F, Bathina S, Armamento-Villareal R. Novel adipokines and their role in bone metabolism: a narrative review. Biomedicines. 2023;11:644.","journal-title":"Biomedicines"},{"issue":"307","key":"644_CR126","first-page":"426","volume":"2005","author":"A Fukuhara","year":"1979","unstructured":"Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 1979;2005(307):426\u201330.","journal-title":"Science"},{"key":"644_CR127","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.2337\/diabetes.54.10.2911","volume":"54","author":"J Berndt","year":"2005","unstructured":"Berndt J, Kl\u00f6ting N, Kralisch S, Kovacs P, Fasshauer M, Sch\u00f6n MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54:2911\u20136.","journal-title":"Diabetes"},{"key":"644_CR128","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.exphem.2013.02.008","volume":"41","author":"SU Venkateshaiah","year":"2013","unstructured":"Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, et al. NAMPT\/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013;41:547-557.e2.","journal-title":"Exp Hematol"},{"key":"644_CR129","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1182\/blood-2012-03-416776","volume":"120","author":"M Cea","year":"2012","unstructured":"Cea M, Cagnetta A, Fulciniti M, Tai Y-T, Hideshima T, Chauhan D, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1\/2) inhibition. Blood. 2012;120:3519\u201329.","journal-title":"Blood"},{"key":"644_CR130","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood-2013-02-483511","volume":"122","author":"A Cagnetta","year":"2013","unstructured":"Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai Y-T, et al. Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013;122:1243\u201355.","journal-title":"Blood"},{"key":"644_CR131","doi-asserted-by":"publisher","first-page":"28175","DOI":"10.1074\/jbc.M700793200","volume":"282","author":"KB Goralski","year":"2007","unstructured":"Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282:28175\u201388.","journal-title":"J Biol Chem"},{"key":"644_CR132","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1210\/en.2007-0175","volume":"148","author":"K Bozaoglu","year":"2007","unstructured":"Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687\u201394.","journal-title":"Endocrinology"},{"key":"644_CR133","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40364-018-0134-y","volume":"6","author":"M Westhrin","year":"2018","unstructured":"Westhrin M, Moen SH, Kristensen IB, Buene G, Mylin AK, Turesson I, et al. Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes. Biomark Res. 2018;6:21.","journal-title":"Biomark Res"},{"key":"644_CR134","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cca.2016.04.001","volume":"457","author":"Y Yang","year":"2016","unstructured":"Yang Y, Lv S-Y, Ye W, Zhang L. Apelin\/APJ system and cancer. Clin Chim Acta. 2016;457:112\u20136.","journal-title":"Clin Chim Acta"},{"key":"644_CR135","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1002\/jcp.30845","volume":"237","author":"J Chen","year":"2022","unstructured":"Chen J, Li Z, Zhao Q, Chen L. Roles of apelin\/APJ system in cancer: biomarker, predictor, and emerging therapeutic target. J Cell Physiol. 2022;237:3734\u201351.","journal-title":"J Cell Physiol"},{"key":"644_CR136","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3233\/CBM-160654","volume":"17","author":"M Maden","year":"2017","unstructured":"Maden M, Pamuk ON, Pamuk GE. High apelin levels could be used as a diagnostic marker in multiple myeloma: a comparative study. Cancer Biomark. 2017;17:391\u20136.","journal-title":"Cancer Biomark"},{"key":"644_CR137","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.3390\/cancers14194656","volume":"14","author":"C Grinstead","year":"2022","unstructured":"Grinstead C, Yoon S. Apelin, a circulating biomarker in cancer evaluation: a systematic review. Cancers (Basel). 2022;14:4656.","journal-title":"Cancers (Basel)"},{"key":"644_CR138","doi-asserted-by":"publisher","first-page":"14982","DOI":"10.3390\/ijms232314982","volume":"23","author":"TV Kirichenko","year":"2022","unstructured":"Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The role of adipokines in inflammatory mechanisms of obesity. Int J Mol Sci. 2022;23:14982.","journal-title":"Int J Mol Sci"},{"key":"644_CR139","doi-asserted-by":"publisher","first-page":"1482308","DOI":"10.3389\/fimmu.2025.1482308","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J, Ding N, Chen C, Gu S, Liu J, Wang Y, et al. Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases. Front Immunol. 2025;16:1482308.","journal-title":"Front Immunol"},{"key":"644_CR140","first-page":"91","volume":"24","author":"H Ji","year":"2019","unstructured":"Ji H, Wan L, Zhang Q, Chen M, Zhao X. The effect of omentin-1 on the proliferation and apoptosis of colon cancer stem cells and the potential mechanism. J BUON. 2019;24:91\u20138.","journal-title":"J BUON"},{"key":"644_CR141","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1186\/s12885-023-11519-5","volume":"23","author":"L Jia","year":"2023","unstructured":"Jia L, Liao L, Jiang Y, Hu X, Lu G, Xiao W, et al. Low-dose adropin stimulates inflammasome activation of macrophage via mitochondrial ROS involved in colorectal cancer progression. BMC Cancer. 2023;23:1042.","journal-title":"BMC Cancer"},{"key":"644_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/5971981","volume":"2022","author":"A-SM Abas","year":"2022","unstructured":"Abas A-SM, Sherif MH, Elmoneam Farag SA. Diagnostic and prognostic role of serum omentin and NGAL levels in egyptian breast cancer patients. Int J Breast Cancer. 2022;2022:1\u20138.","journal-title":"Int J Breast Cancer"},{"key":"644_CR143","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3390\/biom11111609","volume":"11","author":"GS Christodoulatos","year":"2021","unstructured":"Christodoulatos GS, Antonakos G, Karampela I, Psallida S, Stratigou T, Vallianou N, et al. Circulating Omentin-1 as a biomarker at the intersection of postmenopausal breast cancer occurrence and cardiometabolic risk: an observational cross-sectional study. Biomolecules. 2021;11:1609.","journal-title":"Biomolecules"},{"key":"644_CR144","doi-asserted-by":"publisher","first-page":"106","DOI":"10.15171\/apb.2020.013","volume":"10","author":"N Tahmasebpour","year":"2019","unstructured":"Tahmasebpour N, Hosseinpour Feizi MA, Ziamajidi N, Pouladi N, Montazeri V, Farhadian M, et al. Association of Omentin-1 with oxidative stress and clinical significances in patients with breast cancer. Adv Pharm Bull. 2019;10:106\u201313.","journal-title":"Adv Pharm Bull"},{"key":"644_CR145","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/01635581.2017.1359314","volume":"69","author":"BG Tuna","year":"2017","unstructured":"Tuna BG, Atalay PB, Altunbek M, Kalkan BM, Dogan S. Effects of chronic and intermittent calorie restriction on adropin levels in breast cancer. Nutr Cancer. 2017;69:1003\u201310.","journal-title":"Nutr Cancer"},{"key":"644_CR146","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.bbamcr.2017.05.001","volume":"1864","author":"A Rao","year":"2017","unstructured":"Rao A, Herr DR. G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. Biochim Biophys Acta (BBA) - Mol Cell Res. 2017;1864:1318\u201327.","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Res"},{"key":"644_CR147","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3390\/jcm9041179","volume":"9","author":"A Borowski","year":"2020","unstructured":"Borowski A, Siemi\u0144ska L. Serum omentin levels in patients with prostate cancer and associations with sex steroids and metabolic syndrome. J Clin Med. 2020;9:1179.","journal-title":"J Clin Med"},{"key":"644_CR148","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s12032-014-0923-6","volume":"31","author":"U Uyeturk","year":"2014","unstructured":"Uyeturk U, Sar\u0131c\u0131 H, K\u0131n Tekce B, Eroglu M, Kemahl\u0131 E, Uyeturk U, et al. Serum omentin level in patients with prostate cancer. Med Oncol. 2014;31:923.","journal-title":"Med Oncol"},{"key":"644_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3852401","volume":"2018","author":"M Fryczkowski","year":"2018","unstructured":"Fryczkowski M, Bu\u0142dak RJ, Hejmo T, Kukla M, \u017bwirska-Korczala K. Circulating levels of omentin, leptin, VEGF, and HGF and their clinical relevance with PSA marker in prostate cancer. Dis Markers. 2018;2018:1\u20139.","journal-title":"Dis Markers"},{"key":"644_CR150","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3109\/09513590.2015.1065480","volume":"31","author":"S Nergiz","year":"2015","unstructured":"Nergiz S, Altinkaya SO, Kurt \u00d6m\u00fcrl\u00fc \u0130, Yuksel H, K\u00fc\u00e7\u00fck M, Demircan SS. Circulating adropin levels in patients with endometrium cancer. Gynecol Endocrinol. 2015;31:730\u20135.","journal-title":"Gynecol Endocrinol"},{"key":"644_CR151","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/diagnostics11030494","volume":"11","author":"K Michalczyk","year":"2021","unstructured":"Michalczyk K, Niklas N, Rychlicka M, Cymbaluk-P\u0142oska A. The influence of biologically active substances secreted by the adipose tissue on endometrial cancer. Diagnostics. 2021;11:494.","journal-title":"Diagnostics"},{"key":"644_CR152","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.3390\/cancers15153797","volume":"15","author":"P Dec","year":"2023","unstructured":"Dec P, Poniewierska-Baran A, Modrzejewski A, Pawlik A. The role of Omentin-1 in cancers development and progression. Cancers (Basel). 2023;15:3797.","journal-title":"Cancers (Basel)"},{"key":"644_CR153","doi-asserted-by":"publisher","first-page":"100299","DOI":"10.1016\/j.metop.2024.100299","volume":"23","author":"S Rooban","year":"2024","unstructured":"Rooban S, Arul Senghor KA, Vinodhini VM, Kumar JS. Adropin: a crucial regulator of cardiovascular health and metabolic balance. Metabol Open. 2024;23:100299.","journal-title":"Metabol Open"},{"key":"644_CR154","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fonc.2018.00103","volume":"8","author":"HD Hosgood","year":"2018","unstructured":"Hosgood HD, Gunter MJ, Murphy N, Rohan TE, Strickler HD. The relation of obesity-related hormonal and cytokine levels with multiple myeloma and non-hodgkin lymphoma. Front Oncol. 2018;8:103.","journal-title":"Front Oncol"},{"key":"644_CR155","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.exphem.2010.06.012","volume":"38","author":"Y Cao","year":"2010","unstructured":"Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, et al. The cytokine\/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol. 2010;38:860\u20137.","journal-title":"Exp Hematol"},{"key":"644_CR156","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood.V91.1.3","volume":"91","author":"M Hallek","year":"1998","unstructured":"Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3\u201321.","journal-title":"Blood"},{"key":"644_CR157","first-page":"98","volume":"47","author":"I Van Riet","year":"1999","unstructured":"Van Riet I. Homing mechanisms of myeloma cells. Pathol Biol (Paris). 1999;47:98\u2013108.","journal-title":"Pathol Biol (Paris)"},{"key":"644_CR158","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/332083a0","volume":"332","author":"M Kawano","year":"1988","unstructured":"Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas. Nature. 1988;332:83\u20135.","journal-title":"Nature"},{"key":"644_CR159","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/ijc.22024","volume":"119","author":"A Zlotnik","year":"2006","unstructured":"Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119:2026\u20139.","journal-title":"Int J Cancer"},{"key":"644_CR160","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00005-008-0022-5","volume":"56","author":"B Zdzisi\u0144ska","year":"2008","unstructured":"Zdzisi\u0144ska B, Bojarska-Junak A, Dmoszy\u0144ska A, Kandefer-Szersze\u0144 M. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz). 2008;56:207\u201321.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"644_CR161","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2007.05.013","volume":"256","author":"D Raman","year":"2007","unstructured":"Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007;256:137\u201365.","journal-title":"Cancer Lett"},{"key":"644_CR162","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","volume":"103","author":"JW Lee","year":"2004","unstructured":"Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 2004;103:2308\u201315.","journal-title":"Blood"},{"key":"644_CR163","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1365-2141.2005.05443.x","volume":"129","author":"A Pellegrino","year":"2005","unstructured":"Pellegrino A, Ria R, Di PG, Cirulli T, Surico G, Pennisi A, et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol. 2005;129:248\u201356.","journal-title":"Br J Haematol"},{"key":"644_CR164","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1182\/blood.V98.2.428","volume":"98","author":"K Podar","year":"2001","unstructured":"Podar K, Tai Y-T, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428\u201335.","journal-title":"Blood"},{"key":"644_CR165","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1074\/jbc.M109068200","volume":"277","author":"K Podar","year":"2002","unstructured":"Podar K, Tai Y-T, Lin BK, Narsimhan RP, Sattler M, Kijima T, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with \u03b21 integrin- and phosphatidylinositol 3-kinase-dependent PKC\u03b1 activation. J Biol Chem. 2002;277:7875\u201381.","journal-title":"J Biol Chem"},{"key":"644_CR166","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000046612","volume":"106","author":"A Vacca","year":"2001","unstructured":"Vacca A, Ribatti D, Roccaro AM, Ria R, Palermo L, Dammacco F. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol. 2001;106:162\u20139.","journal-title":"Acta Haematol"},{"key":"644_CR167","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1084\/jem.190.2.293","volume":"190","author":"S Niida","year":"1999","unstructured":"Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med. 1999;190:293\u20138.","journal-title":"J Exp Med"},{"key":"644_CR168","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","volume":"13","author":"Y Tanaka","year":"2007","unstructured":"Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res. 2007;13:816\u201323.","journal-title":"Clin Cancer Res"},{"key":"644_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/1852517","volume":"2017","author":"C Musolino","year":"2017","unstructured":"Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S. Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma. Mediators Inflamm. 2017;2017:1\u201324.","journal-title":"Mediators Inflamm"},{"key":"644_CR170","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3389\/fendo.2018.00788","volume":"9","author":"D Harmer","year":"2018","unstructured":"Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne). 2018;9:788.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"644_CR171","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.24352","volume":"91","author":"JA Lust","year":"2016","unstructured":"Lust JA, Lacy MQ, Zeldenrust SR, Witzig TE, Moon-Tasson LL, Dinarello CA, et al. Reduction in C-reactive protein indicates successful targeting of the IL-1\/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am J Hematol. 2016;91:571\u20134.","journal-title":"Am J Hematol"},{"key":"644_CR172","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/bmt.2017.228","volume":"53","author":"R Chakraborty","year":"2018","unstructured":"Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, et al. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplant. 2018;53:155\u201361.","journal-title":"Bone Marrow Transplant"},{"key":"644_CR173","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ccr.2007.08.008","volume":"12","author":"J Yang","year":"2007","unstructured":"Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell. 2007;12:252\u201365.","journal-title":"Cancer Cell"},{"key":"644_CR174","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1056\/NEJM198708273170902","volume":"317","author":"IR Garrett","year":"1987","unstructured":"Garrett IR, Durie BG, Nedwin GE, Gillespie A, Bringman T, Sabatini M, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med. 1987;317:526\u201332.","journal-title":"N Engl J Med"},{"key":"644_CR175","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519\u201327.","journal-title":"Oncogene"},{"key":"644_CR176","doi-asserted-by":"publisher","first-page":"48732","DOI":"10.18632\/oncotarget.8982","volume":"7","author":"L Bieghs","year":"2016","unstructured":"Bieghs L, Johnsen HE, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, et al. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Oncotarget. 2016;7:48732\u201352.","journal-title":"Oncotarget"},{"key":"644_CR177","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1046\/j.1365-2141.1997.592708.x","volume":"97","author":"F Xu","year":"1997","unstructured":"Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol. 1997;97:429\u201340.","journal-title":"Br J Haematol"},{"key":"644_CR178","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/sj.leu.2403076","volume":"17","author":"R Ria","year":"2003","unstructured":"Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003;17:1961\u20136.","journal-title":"Leukemia"},{"key":"644_CR179","first-page":"5736","volume":"61","author":"RE Bachelder","year":"2001","unstructured":"Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001;61:5736\u201340.","journal-title":"Cancer Res"},{"key":"644_CR180","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0002-9440(10)61736-1","volume":"159","author":"S Soker","year":"2001","unstructured":"Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol. 2001;159:651\u20139.","journal-title":"Am J Pathol"},{"key":"644_CR181","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0002-9440(10)65539-3","volume":"153","author":"RF Nicosia","year":"1998","unstructured":"Nicosia RF. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol. 1998;153:11\u20136.","journal-title":"Am J Pathol"},{"key":"644_CR182","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","volume":"95","author":"B Dankbar","year":"2000","unstructured":"Dankbar B, Padr\u00f3 T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630\u20136.","journal-title":"Blood"},{"key":"644_CR183","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1046\/j.1365-2141.1996.d01-1470.x","volume":"92","author":"K Pulkki","year":"1996","unstructured":"Pulkki K, Pelliniemi T, Rajam\u00e4ki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol. 1996;92:370\u20134.","journal-title":"Br J Haematol"},{"key":"644_CR184","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"G Neufeld","year":"1999","unstructured":"Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9\u201322.","journal-title":"FASEB J"},{"key":"644_CR185","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","volume":"473","author":"M Nakagawa","year":"2000","unstructured":"Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett. 2000;473:161\u20134.","journal-title":"FEBS Lett"},{"key":"644_CR186","unstructured":"Say\u0131n S, Kutlu R, Kulaks\u0131zo\u011flu M. The relationship between sex steroids, insulin resistance and body compositions in obese women: a case-control study. J Med Biochem.\u00a02020;39(1):25\u201331."},{"key":"644_CR187","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.fertnstert.2005.10.054","volume":"85","author":"R Pasquali","year":"2006","unstructured":"Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006;85:1319\u201340.","journal-title":"Fertil Steril"},{"key":"644_CR188","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1080\/10428194.2018.1538511","volume":"60","author":"M Ozerova","year":"2019","unstructured":"Ozerova M, Nefedova Y. Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC. Leuk Lymphoma. 2019;60:1557\u201362.","journal-title":"Leuk Lymphoma"},{"key":"644_CR189","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/jbmr.4507","volume":"37","author":"Y Cui","year":"2020","unstructured":"Cui Y, Wang F, Zhang D, Huang J, Yang Y, Xu J, et al. Estrogen-responsive gene MAST4 regulates myeloma bone disease. J Bone Miner Res. 2020;37:711\u201323.","journal-title":"J Bone Miner Res"},{"key":"644_CR190","first-page":"6429","volume":"48","author":"JP Peyrat","year":"1988","unstructured":"Peyrat JP, Bonneterre J, Beuscart R, Djiane J, Demaille A. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res. 1988;48:6429\u201333.","journal-title":"Cancer Res"},{"key":"644_CR191","first-page":"1067","volume":"12","author":"H Yu","year":"2003","unstructured":"Yu H, Shu X-O, Li BDL, Dai Q, Gao Y-T, Jin F, et al. Joint effect of insulin-like growth factors and sex steroids on breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:1067\u201373.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"644_CR192","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/A:1006127621512","volume":"52","author":"MJ Ellis","year":"1998","unstructured":"Ellis MJ, Jenkins S, Hanfelt J, Redington ME, Taylor M, Leek R, et al. Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat. 1998;52:175\u201384.","journal-title":"Breast Cancer Res Treat"},{"key":"644_CR193","doi-asserted-by":"publisher","first-page":"31839","DOI":"10.1074\/jbc.M105185200","volume":"276","author":"LH Wang","year":"2001","unstructured":"Wang LH, Yang XY, Mihalic K, Xiao W, Li D, Farrar WL. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J Biol Chem. 2001;276:31839\u201344.","journal-title":"J Biol Chem"},{"key":"644_CR194","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cen.13723","volume":"89","author":"M Grossmann","year":"2018","unstructured":"Grossmann M. Hypogonadism and male obesity: focus on unresolved questions. Clin Endocrinol (Oxf). 2018;89:11\u201321.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"644_CR195","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1080\/10428194.2018.1508664","volume":"60","author":"S John","year":"2019","unstructured":"John S, Sharma N, Sborov DW, Williams N, Jones D, Benson DM, et al. Most multiple myeloma patients have low testosterone. Leuk Lymphoma. 2019;60:836\u20138.","journal-title":"Leuk Lymphoma"},{"key":"644_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/eje.0.1510001","volume":"151","author":"A Tchernof","year":"2004","unstructured":"Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol. 2004;151:1\u201314.","journal-title":"Eur J Endocrinol"},{"key":"644_CR197","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1158\/0008-5472.CAN-04-3079","volume":"65","author":"S Liu","year":"2005","unstructured":"Liu S, Ishikawa H, Li F-J, Ma Z, Otsuyama K, Asaoku H, et al. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma. Cancer Res. 2005;65:2269\u201376.","journal-title":"Cancer Res"},{"key":"644_CR198","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","volume":"3","author":"I Elia","year":"2021","unstructured":"Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3:21\u201332.","journal-title":"Nat Metab"},{"key":"644_CR199","doi-asserted-by":"publisher","first-page":"e0119857","DOI":"10.1371\/journal.pone.0119857","volume":"10","author":"KA Zub","year":"2015","unstructured":"Zub KA, de Sousa MML, Sarno A, Sharma A, Demirovic A, Rao S, et al. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells. PLoS ONE. 2015;10:e0119857.","journal-title":"PLoS ONE"},{"key":"644_CR200","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1182\/blood-2011-09-377846","volume":"119","author":"SK McBrayer","year":"2012","unstructured":"McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST, Shanmugam M. Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood. 2012;119:4686\u201397.","journal-title":"Blood"},{"key":"644_CR201","doi-asserted-by":"publisher","first-page":"100974","DOI":"10.1016\/j.neo.2024.100974","volume":"50","author":"X Zhou","year":"2024","unstructured":"Zhou X, He R, Hu W-X, Luo S, Hu J. Targeting myeloma metabolism: how abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors. Neoplasia. 2024;50:100974.","journal-title":"Neoplasia"},{"key":"644_CR202","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00277-011-1246-8","volume":"91","author":"JM Tirado-V\u00e9lez","year":"2012","unstructured":"Tirado-V\u00e9lez JM, Ben\u00edtez-Rond\u00e1n A, C\u00f3zar-Castellano I, Medina F, Perdomo G. Low-density lipoprotein cholesterol suppresses apoptosis in human multiple myeloma cells. Ann Hematol. 2012;91:83\u20138.","journal-title":"Ann Hematol"},{"key":"644_CR203","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood.2019001034","volume":"134","author":"Y Tabe","year":"2019","unstructured":"Tabe Y, Lorenzi PL, Konopleva M. Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood. 2019;134:1014\u201323.","journal-title":"Blood"},{"key":"644_CR204","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.3390\/cancers14225637","volume":"14","author":"C-H Tseng","year":"2022","unstructured":"Tseng C-H. The risk of multiple myeloma is reduced in metformin initiators: a retrospective cohort study in Taiwanese patients with type 2 diabetes mellitus. Cancers (Basel). 2022;14:5637.","journal-title":"Cancers (Basel)"},{"key":"644_CR205","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1016\/j.clml.2020.07.003","volume":"20","author":"A Afzal","year":"2020","unstructured":"Afzal A, Fiala MA, Gage BF, Wildes TM, Sanfilippo K. Statins reduce mortality in multiple myeloma: a population-based US study. Clin Lymphoma Myeloma Leuk. 2020;20:e937\u201343.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"644_CR206","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood.V126.23.4198.4198","volume":"126","author":"BC-H Chiu","year":"2015","unstructured":"Chiu BC-H, Chen J-H, Yen Y-C, Calip GS, Chien C-R, Ahsan H, et al. Long term statin use and risk of multiple myeloma among 15.5 million Taiwanese adults: a retrospective cohort study. Blood. 2015;126:4198\u20134198.","journal-title":"Blood"},{"key":"644_CR207","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.30745","volume":"141","author":"MM Epstein","year":"2017","unstructured":"Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, et al. Statin use and risk of multiple myeloma: an analysis from the cancer research network. Int J Cancer. 2017;141:480\u20137.","journal-title":"Int J Cancer"},{"key":"644_CR208","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ajh.25778","volume":"95","author":"E Br\u00e5nvall","year":"2020","unstructured":"Br\u00e5nvall E, Ekberg S, Eloranta S, W\u00e4sterlid T, Birmann BM, Smedby KE. Statin use is associated with improved survival in multiple myeloma: a Swedish population-based study of 4315 patients. Am J Hematol. 2020;95:652\u201361.","journal-title":"Am J Hematol"},{"key":"644_CR209","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:234.","journal-title":"Signal Transduct Target Ther"},{"key":"644_CR210","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.bbmt.2019.01.036","volume":"25","author":"MS Ebbesen","year":"2019","unstructured":"Ebbesen MS, Kissow H, Hartmann B, Grell K, G\u00f8rl\u00f8v JS, Kielsen K, et al. Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1085\u201391.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"644_CR211","doi-asserted-by":"publisher","first-page":"pkae095","DOI":"10.1093\/jncics\/pkae095","volume":"8","author":"N Grandhi","year":"2024","unstructured":"Grandhi N, Liu L, Wang M, Thomas T, Schoen M, Sanfilippo K, et al. Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes. JNCI Cancer Spectr. 2024;8(6):pkae095.","journal-title":"JNCI Cancer Spectr"},{"key":"644_CR212","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024;7:e2421305.","journal-title":"JAMA Netw Open"},{"key":"644_CR213","doi-asserted-by":"publisher","unstructured":"Chang Y-C, Peng C-Y, Chi K-Y, Song J, Chang Y, Chiang C-H, et al. Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf017.","DOI":"10.1093\/eurjpc\/zwaf017"},{"key":"644_CR214","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor \u03b3 (PPAR\u03b3). J Biol Chem. 1995;270:12953\u20136.","journal-title":"J Biol Chem"},{"key":"644_CR215","doi-asserted-by":"publisher","first-page":"215832","DOI":"10.1016\/j.canlet.2022.215832","volume":"545","author":"Y Sha","year":"2022","unstructured":"Sha Y, Wu J, Paul B, Zhao Y, Mathews P, Li Z, et al. PPAR agonists attenuate lenalidomide\u2019s anti-myeloma activity in vitro and in vivo. Cancer Lett. 2022;545:215832.","journal-title":"Cancer Lett"},{"key":"644_CR216","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.3390\/cancers14215272","volume":"14","author":"J Wu","year":"2022","unstructured":"Wu J, Chu E, Paul B, Kang Y. Mechanistic studies and a retrospective cohort study: the interaction between PPAR agonists and immunomodulatory agents in multiple myeloma. Cancers (Basel). 2022;14:5272.","journal-title":"Cancers (Basel)"},{"key":"644_CR217","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3390\/cells12151993","volume":"12","author":"J Wu","year":"2023","unstructured":"Wu J, Wang X, Zhang M, Mathews P, Kang Y. RXR agonists enhance lenalidomide anti-myeloma activity and T cell functions while retaining glucose-lowering effect. Cells. 2023;12:1993.","journal-title":"Cells"},{"key":"644_CR218","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1365-2141.2009.07902.x","volume":"147","author":"N Aouali","year":"2009","unstructured":"Aouali N, Palissot V, El-Khoury V, Moussay E, Janji B, Pierson S, et al. Peroxisome proliferator-activated receptor \u03b3 agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells. Br J Haematol. 2009;147:662\u201371.","journal-title":"Br J Haematol"},{"key":"644_CR219","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1074-7613(04)00030-5","volume":"20","author":"LH Wang","year":"2004","unstructured":"Wang LH, Yang XY, Zhang X, Huang J, Hou J, Li J, et al. Transcriptional inactivation of STAT3 by PPAR\u03b3 suppresses IL-6-responsive multiple myeloma cells. Immunity. 2004;20:205\u201318.","journal-title":"Immunity"},{"key":"644_CR220","doi-asserted-by":"publisher","first-page":"e0130339","DOI":"10.1371\/journal.pone.0130339","volume":"10","author":"N Aouali","year":"2015","unstructured":"Aouali N, Broukou A, Bosseler M, Keunen O, Schlesser V, Janji B, et al. Epigenetic activity of peroxisome proliferator-activated receptor gamma agonists increases the anticancer effect of histone deacetylase inhibitors on multiple myeloma cells. PLoS ONE. 2015;10:e0130339.","journal-title":"PLoS ONE"},{"key":"644_CR221","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/00001813-200411000-00004","volume":"15","author":"J Eucker","year":"2004","unstructured":"Eucker J, B\u00e4ngeroth K, Zavrski I, Krebbel H, Zang C, Heider U, et al. Ligands of peroxisome proliferator-activated receptor \u03b3 induce apoptosis in multiple myeloma. Anticancer Drugs. 2004;15:955\u201360.","journal-title":"Anticancer Drugs"},{"key":"644_CR222","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1182\/blood-2006-07-038026","volume":"110","author":"LH Wang","year":"2007","unstructured":"Wang LH, Yang XY, Zhang X, Farrar WL. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPAR\u03b3 cross talk with NF-\u03baB and C\/EBP\u03b2. Blood. 2007;110:4373\u201384.","journal-title":"Blood"},{"key":"644_CR223","doi-asserted-by":"publisher","first-page":"14189","DOI":"10.1038\/s41598-019-50591-5","volume":"9","author":"SWZ Olechnowicz","year":"2019","unstructured":"Olechnowicz SWZ, Weivoda MM, Lwin ST, Leung SK, Gooding S, Nador G, et al. Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment. Sci Rep. 2019;9:14189.","journal-title":"Sci Rep"},{"key":"644_CR224","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","volume":"49","author":"LT Bloedon","year":"2008","unstructured":"Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008;49:1344\u201352.","journal-title":"J Lipid Res"},{"key":"644_CR225","doi-asserted-by":"publisher","first-page":"pkz054","DOI":"10.1093\/jncics\/pkz054","volume":"3","author":"J Luo","year":"2019","unstructured":"Luo J, Hendryx M, Manson JE, Figueiredo JC, LeBlanc ES, Barrington W, et al. Intentional weight loss and obesity-related cancer risk. JNCI Cancer Spectr. 2019;3:pkz054.","journal-title":"JNCI Cancer Spectr"},{"key":"644_CR226","doi-asserted-by":"publisher","first-page":"378S","DOI":"10.3945\/ajcn.113.071266","volume":"100","author":"TJ Key","year":"2014","unstructured":"Key TJ, Appleby PN, Crowe FL, Bradbury KE, Schmidt JA, Travis RC. Cancer in British vegetarians: updated analyses of 4998 incident cancers in a cohort of 32,491 meat eaters, 8612 fish eaters, 18,298 vegetarians, and 2246 vegans. Am J Clin Nutr. 2014;100:378S-385S.","journal-title":"Am J Clin Nutr"},{"key":"644_CR227","doi-asserted-by":"publisher","first-page":"pkz025","DOI":"10.1093\/jncics\/pkz025","volume":"3","author":"DH Lee","year":"2019","unstructured":"Lee DH, Fung TT, Tabung FK, Colditz GA, Ghobrial IM, Rosner BA, et al. Dietary pattern and risk of multiple myeloma in two large prospective US cohort studies. JNCI Cancer Spectr. 2019;3:pkz025.","journal-title":"JNCI Cancer Spectr"},{"key":"644_CR228","doi-asserted-by":"publisher","first-page":"e0206047","DOI":"10.1371\/journal.pone.0206047","volume":"13","author":"M Thordardottir","year":"2018","unstructured":"Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Steingrimsdottir L, et al. Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS ONE. 2018;13:e0206047.","journal-title":"PLoS ONE"},{"key":"644_CR229","doi-asserted-by":"publisher","first-page":"12556","DOI":"10.1182\/blood-2022-167423","volume":"140","author":"JM Joseph","year":"2022","unstructured":"Joseph JM, Tang L, Hillengass J, Moysich K, Landgren O, Usmani S, et al. Low intake of fruits and vegetables and high intake of processed meats and juices are associated with risk of MGUS in the National Health and Nutrition Examination Survey (NHANES) database. Blood. 2022;140:12556\u20138.","journal-title":"Blood"},{"key":"644_CR230","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10552-007-9047-z","volume":"18","author":"HD Hosgood","year":"2007","unstructured":"Hosgood HD, Baris D, Zahm SH, Zheng T, Cross AJ. Diet and risk of multiple myeloma in Connecticut women. Cancer Causes Control. 2007;18:1065\u201376.","journal-title":"Cancer Causes Control"},{"key":"644_CR231","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1023\/A:1008937901586","volume":"12","author":"LM Brown","year":"2001","unstructured":"Brown LM, Gridley G, Pottern LM, Baris D, Swanson CA, Silverman DT, et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control. 2001;12:117\u201325.","journal-title":"Cancer Causes Control"},{"key":"644_CR232","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/(SICI)1097-0215(19980703)77:1<24::AID-IJC5>3.0.CO;2-1","volume":"77","author":"L Chatenoud","year":"1998","unstructured":"Chatenoud L, Tavani A, La Vecchia C, Jacobs DR, Negri E, Levi F, et al. Whole grain food intake and cancer risk. Int J Cancer. 1998;77:24\u20138.","journal-title":"Int J Cancer"},{"key":"644_CR233","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1182\/blood-2022-163281","volume":"140","author":"UA Shah","year":"2022","unstructured":"Shah UA, Derkach A, Castro F, Anuraj A, Blaslov J, Tran L, et al. A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of progression. Blood. 2022;140:5066\u20139.","journal-title":"Blood"},{"key":"644_CR234","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/ijc.34011","volume":"151","author":"M Sun","year":"2022","unstructured":"Sun M, Bj\u00f8rge T, Teleka S, Engeland A, Wennberg P, H\u00e4ggstr\u00f6m C, et al. Interaction of leisure-time physical activity with body mass index on the risk of obesity-related cancers: a pooled study. Int J Cancer. 2022;151:859\u201368.","journal-title":"Int J Cancer"},{"key":"644_CR235","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13104-021-05591-y","volume":"14","author":"CSY Lecat","year":"2021","unstructured":"Lecat CSY, McCourt O, Land J, Yong K, Fisher A. Multiple myeloma and physical activity. BMC Res Notes. 2021;14:171.","journal-title":"BMC Res Notes"},{"key":"644_CR236","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1053\/j.gastro.2021.03.021","volume":"161","author":"VK Rustgi","year":"2021","unstructured":"Rustgi VK, Li Y, Gupta K, Minacapelli CD, Bhurwal A, Catalano C, et al. Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity. Gastroenterology. 2021;161:171-184.e10.","journal-title":"Gastroenterology"},{"key":"644_CR237","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s11695-024-07059-x","volume":"34","author":"Q Wu","year":"2024","unstructured":"Wu Q, Zhao T, Zhu C, Da M. Correlation between bariatric surgery and the risk of multiple myeloma: results from an evidence-based strategy. Obes Surg. 2024;34:1061\u201372.","journal-title":"Obes Surg"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00644-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-025-00644-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00644-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T11:03:30Z","timestamp":1749121410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-025-00644-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":237,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1007\/s13679-025-00644-w","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"19 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors have no conficts of interest to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"52"}}